Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

43%

3 of 7 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

5(62.5%)

Phase 1

2(25.0%)

Phase 3

1(12.5%)

8Total

Phase 2(5)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT02059642Phase 2Completed

A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )

Role: lead

NCT00995085Phase 1Completed

Efficacy Study of Metadoxine SR Formulation in Attention Deficit Hyperactivity Disorder (ADHD) Subjects

Role: lead

NCT02477748Phase 3Terminated

The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD

Role: lead

NCT02126995Phase 2Completed

A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome

Role: lead

NCT02189772Phase 2Completed

Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects

Role: lead

NCT01933997Phase 1Completed

A Phase 1 Study to Assess Pharmacokinetics of Metadoxine (MG01CI) 1400 mg, Administered to Healthy Volunteers

Role: lead

NCT01685281Phase 2Completed

Study Comparing Two Doses of MG01CI and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder

Role: lead

NCT01243242Phase 2Completed

Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD)

Role: lead

All 8 trials loaded